



CODEN [USA]: IAJPBB

ISSN: 2349-7750

**INDO AMERICAN JOURNAL OF  
PHARMACEUTICAL SCIENCES**<http://doi.org/10.5281/zenodo.1050439>Available online at: <http://www.iajps.com>

Research Article

**FORMULATION AND EVALUATION OF FLOATING  
MICROSPHERES OF METFORMIN HYDROCHLORIDE**Surendranath Betala<sup>1\*</sup>, M.Mohan Varma<sup>2</sup>, K.Abbulu<sup>3</sup><sup>1</sup>Sri Vasavi Institute of Pharmaceutical Sciences, Tadepalligudem, Andhra Pradesh, India<sup>2</sup>Sri Vishnu College of Pharmacy, Bhimavaram, Andhra Pradesh, India<sup>3</sup>CMR College of Pharmacy, Hyderabad, Telangana, India**Abstract:**

*Metformin hydrochloride is a hypoglycemic agent used for the treatment of non-insulin dependent Diabetes mellitus. It is a BCS class III drug having high solubility and poor permeability. Plasma half life ranges from 1.5 to 3 hours and oral bioavailability is 50 to 60 %. Hence require frequent oral administration for adequate treatment of Diabetes. In order to extend the gastric retention time, oral sustained release dosage form was develop in the form of microspheres using different polymers (sodium CMC, HPMC K100M). All the formulations were evaluated for in-vitro dissolution, entrapment efficiency, and percentage buoyancy. Metformin hydrochloride microspheres of formulation F-4 was optimized on the basis of in-vitro drug release pattern, entrapment efficiency, percentage buoyancy. The percentage yield of optimized formulation was 72%, entrapment efficiency was 70.56%, percentage buoyancy was 86% and the cumulative percentage drug release after 11 hours was found to be 90%. The optimized formulation was tested for its stability for 6 months as per ICH guidelines and the formulation found tom be stable during the test period.*

**Keywords:** Hypoglycemic agent, Diabetes mellitus, Entrapment efficiency, Microspheres.**Corresponding author:****Surendranath Betala,**

Sri Vasavi Institute of Pharmaceutical Sciences,

Tadepalligudem, West Godavari,

Andhra Pradesh, India-534101

Email: [surendrapharma05@gmail.com](mailto:surendrapharma05@gmail.com)

Phone: 91-9866910906

QR code



Please cite this article in press as Surendranath Betala *et al.*, **Formulation and Evaluation of Floating Microspheres of Metformin Hydrochloride**, *Indo Am. J. P. Sci*, 2017; 4(11).

**INTRODUCTION:**

Microspheres are small spherical particles, with diameters in the micrometer range (typically 1  $\mu\text{m}$  to 1000  $\mu\text{m}$  (1 mm)). Microspheres are sometimes referred to as microparticles. Microspheres can be manufactured from various natural and synthetic materials. Glass microspheres, polymer microspheres and ceramic microspheres are commercially available. Solid and hollow microspheres vary widely in density and, therefore, are used for different applications. Hollow microspheres are typically used as additives to lower the density of a material. Solid microspheres have numerous applications depending on what material they are constructed of and what size they are.[1]

**TYPES OF MICROSPHERES** [1, 2]**1. Bio adhesive microspheres**

Adhesion can be defined as sticking of drug to the membrane by using the sticking property of the water soluble polymers. Adhesion of drug delivery device to the mucosal membrane such as buccal, ocular, rectal, nasal etc can be termed as bio adhesion. The term "bioadhesion" describes materials that bind to biological substrates', such as mucosal members. Adhesion of bioadhesive drug delivery devices to the mucosal tissue offers the possibility of creating an intimate and prolonged contact at the site of administration. [3, 4, 5]

This prolonged residence time can result in enhanced absorption and in combination with a controlled release of drug also improved patient compliance by reducing the frequency of administration. Carrier technology offers an intelligent approach for drug delivery by coupling the drug to a carrier particle such as microspheres, nanospheres, liposomes, nanoparticles, etc., which modulates the release and absorption of the drug. Microspheres constitute an important part of these particulate drug delivery systems by virtue of their small size and efficient carrier capacity.

**2. Magnetic microspheres**

This kind of delivery system is very much important which localizes the drug to the disease site. In this larger amount of freely circulating drug can be replaced by smaller amount of magnetically targeted drug. Magnetic carriers receive magnetic responses to a magnetic field from incorporated materials that are used for magnetic microspheres are chitosan, dextran etc. The different type are Therapeutic magnetic microspheres are used to deliver chemotherapeutic agent to liver tumor. Drugs like proteins and peptides can also be targeted through this system. Diagnostic microspheres. Magnetic drug transport technique is

based on the fact that the drug can be either encapsulated into a magnetic microsphere or conjugated on the surface of the microsphere. The accumulation of carrier at the target site allows them to deliver the drug locally.

**3. Floating microspheres**

In floating types the bulk density is less than the gastric fluid and so remains buoyant in stomach without affecting gastric emptying rate. The drug is released slowly at the desired rate, if the system is floating on gastric content, increases gastric residence and fluctuation in plasma concentration. It also reduces chances of striking and dose dumping and produces prolonged therapeutic effect. Drug (ketoprofen) given through this form.[1,6,8]

**4. Radioactive microspheres**

Radio embolisation therapy microspheres sized 10-30 nm are of larger than capillaries and gets trapped in first capillary bed when they come across. They are injected to the arteries that lead to tumor of interest. So these radioactive microspheres deliver high radiation dose to the targeted areas without damaging the normal surrounding tissues. It differs from drug delivery system, as radio activity is not released from microspheres but acts from within a radioisotope typical distance and the different kinds of radioactive microspheres are  $\alpha$  emitters,  $\beta$  emitters,  $\gamma$  emitters.[12]

**5. Muco adhesive microspheres**

Muco adhesive microspheres which are of 1-1000mm in diameter and consisting either entirely of a muco adhesive polymer or having an outer coating of it and coupling of mucoadhesive properties to microspheres has additional advantages, e.g. efficient absorption and enhanced bioavailability of the drugs due to a high surface to volume ratio, a much more intimate contact with the mucus layer, specific targeting of drug to the absorption site achieved by anchoring plant lectins, bacterial adhesions and antibodies, etc. on the surface of the microspheres. Mucoadhesive microspheres can be tailored to adhere to any mucosal tissue including those found in eye, nasal cavity, urinary and gastrointestinal tract, thus offering the possibilities of localized as well as systemic controlled release of drugs.

**6. Polymeric microspheres** [9,10,11]

The different types of polymeric microspheres can be classified as

**(a) Biodegradable polymeric microspheres:**

Natural polymers such as starch are used with the concept that they are biodegradable, biocompatible, and also Bioadhesive in nature. Biodegradable

polymers prolongs the residence time when contact with mucous membrane due to its high degree of swelling property with aqueous medium, results gel formation. The rate and extent of drug release is controlled by concentration of polymer and the release pattern in a sustained manner. The main drawback is, in clinical use drug loading efficiency of biodegradable microspheres is complex and is difficult to control the drug release.

#### (b) Synthetic polymeric microspheres:

The interest of synthetic polymeric microspheres are widely used in clinical application, moreover that also used as bulking agent, fillers, embolic particles, drug delivery vehicles etc and proved to be safe and biocompatible. But the main disadvantage of these kind, are tend to migrate away from injection site and lead to potential risk, embolism and further organ damage. Polyethylene, polystyrene and expandable microspheres are the most common types of polymer microspheres. [13,14]

### MATERIALS AND METHODS:

**Table 1: Materials used for the study**

INGREDIENTS	SUPPLIER
Metformin hydrochloride	Yarrow chem. Products Mumbai.
Hydroxy propyl methyl cellulose K100M	Ozone International Mumbai.
Sodium Carboxy methyl cellulose	Ozone International Mumbai.
Sodium bicarbonate	S.D. Fine chemicals Ltd, Mumbai.
Calcium chloride	S.D. Fine chemicals Ltd, Mumbai.
Sodium alginate	Loba Chemie Pvt .Ltd.Mumbai.

#### DRUG PROFILE [24,25]

**Empirical formula:** The Empirical formula of Metformin HCl is  $C_4H_{11}N_5 HCl$ .

**Molecular weight:** 165.63.


#### Description:

A biguande hypoglycemic agent used in the treatment of non-insulin dependent diabetes mellitus not responding to dietary modification. Metformin

improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose.

**Melting point:** 223-226 °C

**Structure:**



**Metformin Hydrochloride**

**Fig 1 : Metformin Hydrochloride structure**

**Chemical name:** 1-carbamimidamido-N,N-dimethylmethanimidamide.

#### Pharmacokinetics:

After oral administration Metformin Hydrochloride is freely soluble. Half-life of Metformin Hydrochloride salt is 4-6 hours. The oral bioavailability of the drug is 50-60 % under fasting conditions.

#### Formulation of Sustained Release Microspheres

**Procedure:** The following steps involved in preparation of Metoprolol microspheres.

1. Preparation of Polymer Solution by dissolving in distilled water.
  2. Dissolve Drug (Metformin Hydrochloride) in above Solution.
  3. Sonicate the Drug-Polymer Solution for proper mixing.
  4. Above solution was added drop wise by a 26G hypodermic needle into 50ml of 5% w/v  $CaCl_2$  solution.
  5. Formed Metoprolol Microspheres were stirred in the cross linking agent for 1hr at 100rpm.
  6. Wash the Microspheres with de-ionized water and dried at 80°C for 2 hour.
  7. Transfer prepared Microspheres to desiccators to maintain the constant Humidity conditions.
- All Formulations were prepared by Ionic Gelation method using different polymers. [7,15,16]

Table 2: Formulations composition

Formulations	Metformin HCl (mg)	HPMC-K100 M(mg)	Sodium Carboxy methyl cellulose(mg)	Sodium bicarbonate(mg)
F <sub>1</sub>	500	100	100	100
F <sub>2</sub>	500	100	50	100
F <sub>3</sub>	500	50	100	100
F <sub>4</sub>	500	50	50	100

## RESULTS AND DISCUSSIONS:

### Preformulation Studies [17,20,21]

#### Drug Excipient compatibility studies:

The compatibility of drug and formulation components is important prerequisite before formulation. It is therefore necessary to confirm that the drug does not react with the polymers and excipients under experimental conditions and affect the shelf life of product or any other unwanted effects on the formulation.

The compatibility study between the drug and the polymer was done by I.R studies. No major peak shift

was observed in the I.R graphs in major functional groups. Based on the compatibility studies obtained by I.R studies, the polymer HPMC K100 M, sodium CMC were taken for the optimization of the formulation, which is compatible with the drug.

#### Calibration Curve

Standard curve of Metformin Hydrochloride by using pH 1.2 HCl buffer

Table 3: Data for standard graph of Metformin Hydrochloride in pH 1.2 HCl buffer at  $\lambda$  max 233 nm

S.NO	Concentration ( $\mu\text{g/ml}$ )	Absorbance
1	0	0
2	10	0.171
3	20	0.353
4	30	0.526
5	40	0.736
6	50	0.889





Fig 2: Calibration curve for Metformin Hydrochloride in pH 1.2HCl buffer.

**Evaluation Tests:****Particle Size****Fig 3: SEM of formulated Microspheres****Percentage Yield:****Table 4: Percentage yield of different formulations**

Formulations	Total weight taken (mg)	Total weight of microspheres (mg)	Percentage yield (%)
F-1	1100	750	68.1
F-2	1050	700	66.6
F-3	1050	750	71.4
F-4	1000	720	72

**Inference:** From the above table the percentage yield of prepared Microspheres was found to be more for the formulation F- 4 (72 %)

**Entrapment Efficiency:** [17,20,21]

In calculation of entrapment efficiency first measure amount of drug loaded in the total microspheres. For this U.V visible spectrophotometer is used for the analysis of drug.

**Table No.5: Entrapment efficiency of the different formulations**

Formulations	Observed drug (mg)	Total amount taken (mg)	Entrapment efficiency(%)
F-1	45	100	67.5
F-2	47	100	65.8
F-3	46	100	69
F-4	49	100	70.56

**Inference:** From the above table Entrapment efficiency was found to be more for the formulation F – 4 i.e. (70.56 %).

**Percentage Buoyancy:****Table 6: Buoyancy percentage of different formulations**

S.NO	Formulation code	Percentage buoyancy
1	F-1	81.66
2	F-2	83.33
3	F-3	85.1
4	F-4	86

**Inference:** From the above table the percentage buoyancy was found to be more for the formulation F -4.

Table 7: Dissolution kinetics for formulation F-4.

Time(hrs)	Absorbance	Conc. ( $\mu\text{g/ml}$ )	Cumulative % drug release	% drug un released	Log% released	Log% unreleased
0.5	0.124	5.3	9.5	90.5	0.9777	1.9566
1	0.250	14.5	26.1	73.9	1.4166	1.8686
2	0.292	16.5	29.7	70.3	1.4727	1.8469
3	0.414	23	41.4	58.6	1.6170	1.7678
4	0.521	26.5	47.7	52.3	1.6785	1.7185
5	0.580	32	57.6	42.4	1.7604	1.6273
6	0.662	37.5	67.5	32.5	1.8293	1.5118
7	0.743	45	81	19	1.9084	1.2787
8	0.783	46	82.8	17.2	1.9180	1.2355
9	0.845	47	84.6	15.4	1.9273	1.1875
10	0.878	48.5	87.3	12.7	1.9410	1.1038
11	0.899	50	90	10	1.9542	1

Table 8: Cumulative % drug release for the formulation F -4

Time(hrs)	% cumulative drug release
0	0
0.5	9.5
1	26.1
2	29.7
3	41.4
4	47.7
5	57.6
6	67.5
7	81
8	82.8
9	84.6
10	87.3
11	90




Fig 4: Dissolution Profile of formulation F-4.

## Comparative Dissolution Profile

Table 9: Comparative dissolution profile for formulation F1 – F4

S.NO	F-1 % CDR	F-2 % CDR	F-3 % CDR	F-4 % CDR
1	0	0	0	0
2	11.08	12.1	19.9	9.5
3	18	21.6	21.6	26.1
4	27	26.1	31.5	29.7
5	31.5	37.8	39.6	41.4
6	37.8	45	46.8	47.7
7	46.8	50.4	54	57.6
8	52.2	59.4	71.1	67.5
9	56.7	69.3	75.6	81
10	67.5	71.1	79.2	82.8
11	73.8	74.7	82.8	84.6
12	75.6	80.1	85.5	87.3
13	81	81	88.2	90






Fig 5: Comparative dissolution profile for formulation F1-F4.

**Inference:** From the above fig the dissolution profile for the formulation F-4 was found to be have the more cumulative % drug release.


## Dissolution – Application of Kinetics of F-4

Table10: Application of kinetics for dissolution profile of formulation F-4.


S.NO	TIME	% CDR	Log % CDR	Log % drug unreleased	Square root time	Log time
1	0.5	9.5	0.9777	1.9566	0.7071	-0.301
2	1	26.1	1.4166	1.8686	1	0
3	2	29.7	1.4727	1.8469	1.414	0.3010
4	3	41.4	1.6170	1.7678	1.732	0.4771
5	4	47.7	1.6785	1.7185	2	0.602
6	5	57.6	1.7604	1.6273	2.236	0.6989
7	6	67.5	1.8293	1.5118	2.449	0.778
8	7	81.0	1.9084	1.2787	2.645	0.845
9	8	82.8	1.9180	1.2355	2.828	0.903
10	9	84.6	1.9273	1.1875	3	0.954
11	10	87.3	1.9410	1.1038	3.167	1
12	11	90	1.9542	1	3.316	1.041

**Zero Order Plot****Fig 6: Zero order plot for optimized formulation F-4****First Order Plot****Fig 7: First Order Plot for optimized formulation F-4**

**Inference:** From the above graphs the  $R^2$  value is (0.977) and for zero order plot  $R^2$  value is (0.957) which indicating that the order of release was first order.

**Higuchi's Plot****Fig 8: Higuchi's plot for optimized formulation F-4**



**Korsmeyer- Peppas Plot****Fig 9: Korsmeyer -Peppas plot for optimized formulation F-4**

**Inference:** As per the above plot Fig No. 17 and Fig No. 18. The  $R^2$  value for Higuchi (0.974) and for Korsmeyer - Peppas plot (0.964), showing that the mechanism of drug release from the formulation was found to be Diffusion controlled release.

**Stability studies:**[27,28]

The accelerated stability study for the formulation at  $40 \pm 2^\circ \text{C}$  and  $75 \pm 5\% \text{RH}$  was conducted for the 3 months, which includes the testing of parameters like identification of physical characters, identified by IR studies, dissolution profile and assay throughout period.

**CONCLUSION:**

The present study reported the development of Metformin Hydrochloride (Anti diabetic drug) loaded floating microspheres with polymers HPMC K100 M, sodium CMC. Sodium bicarbonate gas generating agent along with calcium chloride as gelling agent was essential to achieve *In-vitro* buoyancy. The drug release from the floating microspheres was sufficiently controlled. The floating microspheres prepared were found to be spherical and free flowing.

Drug release kinetics performed for ideal formulations, fitted best with zero order plot and Korsmeyer-Peppas equation based on the highest " $R^2$ " value. The  $R^2$  value of Korsmeyer-Peppas equation indicated non-Fickian diffusion controlled released. The selected formulations were subjected to stability studies which indicated that the formulation were stable and retained their pharmaceutical properties at room temperature and  $45^\circ \text{C} / 75\% \text{RH}$  over a period of 3 month. Based on the results the best formulation  $F_4$  can successfully be employed as a controlled release floating drug delivery system. The floating Microspheres can control the fluctuations in the plasma drug concentration,

increase the gastric residence time and eventually improve the bioavailability of the drug. Floating Microspheres were prepared using Iontropic gelation method. From the findings obtained, it was concluded that:

- Compatibility studies revealed no interactions between the drug and polymers used.
- Formulated Microspheres gave satisfactory result for various physic- chemical evaluations like physical appearance, surface morphology, entrapment efficiency, percentage drug loading, percentage buoyancy and *In-vitro* drug release.
- The prepared beads showed required drug release in about 12 hours as aimed for.
- From the research, it can be concluded that Metformin Hydrochloride can be formulated as Microspheres for the desired use in treatment of Diabetes Mellitus.

**REFERENCES:**

1. Chein Y.W, Novel Drug Delivery System : Fundamentals and applications , 2<sup>nd</sup> ed: Marcel Dekker ; New York : (1992) pg.No:4-56.
2. Biopharmaceutics and pharmacokinetics a Treatise D.M. Brahmankar, Sunil B. Jaiswal pg.No:488
3. A.V. Yadav H. mote, Development of Biodegradable starch for Intranasal Delivery , Indian Journal of Pharmaceutical Sciences, (2008), 70(2) ; 170-174.
4. G.V. Mooter , Colon Drug Delivery Exp.opin. Drug delivery , (2006) ;3: 111 -125.

- H.Berkel, R.F. Holcomle, m.Middle, blcooks and R.Kannam, Non-steroidal anti-inflammatory drug and colorectal cancer, *epidermal Rev*; (1996); 18: 205-217.
- 5.J.P,Soarse, J.E.Santos, J.O.Chierce and E.T.G Cavatheiro, Thermal behaviour of alginic acid and its sodium salt, *ECL. Quimsao Paulo* (2004); 29: 53-56.
6. Desai S, Bolton S. A Floating Controlled Release system: In-vitro and In-vivo evaluation, *J. Pharm Res.*, (1986); 3; P.208-213.
- 7.Patel H, Patel R, Patel G. Iontropic Gelation Technique for Microencapsulation of Antihypertensive drug. *WebmedCentral pharmaceutical sciences* 2010;1(10).
8. Ghodake J.D, Vidhate J.S, Shinde D.A, Kadam A.N. "Formulation of Floating Microsphere containing Anti-diabetic Drug". *International Journal of PharmTech* Vol.2, no.1, pp 378-384. (2010).
- 9.Sreenivasulu.S, Harish Nayari M, Brijesh Yadav, Narayana Charyulu R, Satyanarayana D, and Subramanayam E.V.S. Formulation and *in vitro* evaluation of gastric oral floating Microspheres of Metformin Hcl. *Indian j.pharm.Educ.Res*2008;42(2):174-183.
10. Vinod KR, Sri AP, Banji D, Anbazhagan S, Vasa S, Sandhya S. Formulation and *in vitro* characterization of lansoprazole floating gastroretentive microspheres by modified non aqueous solvent evaporation method. *Der Pharm. Chemica*. 2010; 2(5): 419-425.
11. Manish Patel P, Patel MM, Patel KN, Patel DR, Patel UL. Designing and evaluation of microspheres of verapamil hydrochloride, effect of methocel. *Research journal of pharmaceutical dosage forms and technology*.2009;1:22-28.
- 12.GattaniY.S.,Floating Multiparticulate drug delivery systems: an overview, *International Journal of Pharma and Bio Sciences*, 2010 Vol(2).
- 13.TanwarYS, Naruka PS, Ojha GR. Development and evaluation of floating microspheres of verapamil hydrochloride. *Brazilian Journal of Pharm. Sci*. 2007; 43(4): 529-534
14. Jain AK, Jain CP. Buoyant microspheres of Famotidine: An Approachable Dosage form for Gastric treatment. *J. Young Pharm. Dec*. 2009; 1(1): 20-23
- 15.Senthilkumar SK, Jaykar B, Kavimani S. Formulation, Characterization and *In vitro* evaluation of floating microsphere containing Rabeprazole sodium. *JITPS*. 2010; 1(6): 274-282.
- 16.Karthikeyan D, Karthikeyan M, Ramasamy C. Development of floating microspheres to improve oral bioavailability of cefpodoxime proxetil. *Acta Pharm. Scientia*. 2010; 52: 101-104.
17. Ghodake. P, Patil Sangamesh A, Belhekar Anaga A, Halligudi Shivraj B, Aminabhavi Tejraj M. preparation and evaluation of floating microspheres with Metformin Hydrochloride. *Journal of pharmacy Research*.2007; 105:2764-2771.
18. Srivastava AK, Ridhurkar DN, Wadhwa S. Floating microspheres of cimetidine: Formulation, and characterization and *in vitro* evaluation. *Acta Pharm*. 2005; 55: 277-285.
19. Kale RD and Tayade PT. a multiple unit floating drug delivery system of piroxicam using Eudragit, HPMC, EC polymers *Indian Journal of Pharmaceutical Sciences*. 2007;69:120-123.
20. Shashikant Barhate D, Yogesh Rupnar S, Rupesh Sonvane M and Rahul Kumar Rahane D. Formulation and evaluation of floating of floating microspheres of Ketorolac Trometamol. *International Journal of Pharma Research and Development*. 2009;1:1-8.
21. Yuveraj Singh Tanwar, Pushpendra Singh Naruka, Garima Rani Ojha Development and evaluation of floating microspheres of Verapamil hydrochloride. *brailian Journal of Pharmaceutical Sciences*. 2007;4:529-534.
22. Narasaiah, Pasha ST, srinivasan S, Ray S. Design and Optimization of a Multiparticulate Gastroretentive Dosage Form Sumanatriptan Succinate floating tablets. *Journal of Pharmaceutical Science and Technology*. 2009; 1: 40-47.
23. Rokhade Ajit P, Patil Sangamesh A, Belhekar Anaga A, Halligudi Shivraj B, Aminabhavi Tejraj M. preparation and evaluation of cellulose acetate butyrate and poly(ethylene oxide) blend microspheres for gastroretentive floating delivery of Repaglinide. *Journal of Applied Polymer science*. 2007;105:2764-2771
24. [http://Drug Bank Metformin \(DB00331\).mht](http://Drug Bank Metformin (DB00331).mht).
25. <http://www.fda/drugd/metformin.com>.
26. Hand Book of Pharmaceutical Excipients fifth Edition. Raymond c. Rowe. Paul J.Sherkey and Sian C Owe. Pg.No: 334, 665.
27. Leon Lachman, Herbet A. Lieberman, Joseph L. Kanig, "The Theory and Practice of Industrial Pharmacy", Varghese Publishing house, Third Edition, pg: 101-104.
28. Danbrow M, Samuelov Y, Zero order drug delivery from double-layered porous films: release rate profiles from ethyl cellulose, Hydroxypropyl cellulose and Polyethylene glycol mixtures, *Journal of Pharmacy and Pharmacology*, 1980, pg: 463-470.